Close

EBNA6

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Plays an essential role for the activation and immortalization of human B-cells. Represses transcription of viral promoters TP1 and Cp through interaction with host RBPJ, and inhibits EBNA2-mediated activation of these promoters. Since Cp is the promoter for all EBNA mRNAs, EBNA6 probably contributes to a negative autoregulatory control loop. Alternatively, EBNA6 also regulates the transcription of the EBV oncogene LMP1 in a cell cycle-dependent manner. Modulates the activity of several host proteins involved in cell cycle regulation including host cyclin A, MYC, RB, p21 and p27 mainly through binding to the host SCF(SKP2) complex. Inhibits the promoter of host H2AX and targets H2AX to proteasomal degradation in order to promote latency and cell proliferation
  • TCR Vector Products

  • TCR Cell Products

Loading...
  • Target Species:
  • TCR Clone:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-C308 Human anti-EBNA6 T cell receptor (CB-C048), pCDTCR1 EBV CB-C048 Human EENLLDFVRF HLA-B*44:05 Lentiviral vector   Add to Cart   Datasheet
TCR-C309 Human anti-EBNA6 T cell receptor (CB-C049), pCDTCR1 EBV CB-C049 Human EENLLDFVRF HLA-B*44:05 Lentiviral vector   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.